| Title |
Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, July 2017
|
| DOI | 10.2147/tcrm.s140023 |
| Pubmed ID | |
| Authors |
Salma M AlDallal |
| Abstract |
Ofatumumab Arzerra(®) is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody's therapeutic effect on chronic lymphocytic leukemia. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 30% |
| Other | 2 | 20% |
| Student > Bachelor | 2 | 20% |
| Student > Ph. D. Student | 1 | 10% |
| Unknown | 2 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 30% |
| Medicine and Dentistry | 2 | 20% |
| Biochemistry, Genetics and Molecular Biology | 1 | 10% |
| Immunology and Microbiology | 1 | 10% |
| Agricultural and Biological Sciences | 1 | 10% |
| Other | 0 | 0% |
| Unknown | 2 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2017.
All research outputs
#16,725,651
of 25,382,440 outputs
Outputs from Therapeutics and Clinical Risk Management
#809
of 1,323 outputs
Outputs of similar age
#198,515
of 326,871 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#15
of 22 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,871 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.